Arcutis Biotherapeutics, Inc. (ARQT) News
Track canonical SquawkNews coverage tagged to ARQT, Arcutis Biotherapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
ARQT - Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
ARQT - Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
EARNINGS | Aug 05, 2026, 08:00 PM UTC
L
ARQT Arcutis expands Board of Directors with appointment of Chris peetz
ARQT Arcutis expands Board of Directors with appointment of Chris peetz
EQUITY | Jul 16, 2026, 01:02 PM UTC
L
Arcutis Biotherapeutics Says FDA Accepted ZORYVE Expansion Filing for Infants With Eczema
() -- Arcutis Biotherapeutics (ARQT) said Wednesday that the FDA accepted its application to expand ZORYVE cream 0.05% for infants with mild-to-moderate atopic dermatitis and has set a PDUFA action date of Feb. 23. The f
REGULATION | Jul 08, 2026, 12:59 PM UTC
L
Arcutis Biotherapeutics announces FDA acceptance of Zoryve sNDA
Arcutis Biotherapeutics announced that the FDA has accepted its supplemental new drug application, or sNDA, for Zoryve cream 0.05% to expand the indication for the topical treatment of mild to moderate atopic dermatitis
EQUITY | Jul 08, 2026, 12:13 PM UTC
L
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?
2026-07-03 08:57:20 ET Choosing between Arcutis Biotherapeutics (NASDAQ:ARQT) and
EQUITY | Jul 03, 2026, 01:02 PM UTC
M
Reported Earlier, Arcutis Expands ZORYVE Label With FDA Approval For Once-Daily Steroid-Free Plaque Psoriasis Treatment In Young Children
ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of age ZORYVE cream 0.3% is safe, effective, and well-tolerated for use anywhere on the bod
REGULATION | Jun 30, 2026, 07:56 AM UTC